TUC





(D #1050001)

14.04.2016.

Project - BUSINESS PRODUCTION CENTER FARMONT EXCERPT FROM BUSINESS PLAN

PROJECT CONTENT AND COMPANY BUSINESS PROFILE

processing of medicinal herbs and forest fruits. sanilary supplies to retail and wholesale, and recently plantation cultivation, purchase and and medium enterprises. Core business is distribution of medicines, medical devices and Farmont M.P. d.o.o. is a company that was founded in 2001,, it belongs to the group of small

with two compatible production programs: nurkets needs, made the decision to realize Investment program - Business Production center Company has within the scope of its development, considering Montenegrin and regional

MEDICINE (DRUGS) PRODUCTION,

AND WILD FRUIT (PLANTATION GROWING AND REPURCHASE), as well as PURCHESING AND PROCESSING OF MEDICINAL AND AROMATIC HERBS MODERN DISTRIBUTIVE CENTER (current activity)

only manufacturer of a wide range of medicines in Montenegro. ictivities with Montenegro Agency for medicines in part of newly built office space inlended for - SECONDARY PRODUCTION OF MEDICINES, With this FARMONT would became m2. FARMONT next to present - MODERN DISTRIBUTIVE ACTIVITY, began validation Daniloveral in the business area of approximately 900 m2 on a total land surface of 12,060 Recent implementation of Phase I of the Project and moving to a new location in Kosic

FARMONT, therefore, consists of:

- Modern distributive centre in newly built business space in Kosic Danilovgrad FARMONT property;
- Secondary medicine production in newly built business space in Kosle Danilovgrad (in phase of validation) - FARMONT property:
- Phurmucy MEDEONFARM Bul. Sv. Petra Cetinjskog br.45, Podgorica long term
- term lease: Pharmacy MEDEONFARM I - Mastine bb (near health center), Podgorica - long
- foundations, earthworks and infrastructure for total primary production of medicines and processing of medicinal herbs and forest fruits) FARMONT property; Phase I, started construction of business centre Phase II of Investment (completed Land in Kosic - Danilovgrad - total area of 12,000 m2, where next to implemented
- seedlings, irrigation system drop by drop on entire complex, and business space of 756 FARMONT property of approximately 93,032 m2 with 100,000 raspherry seedlings and Agricultural Cooperative in northern Montenegro Murino - Municipalities Play, area with installed cooler, dryer and chambers for frozen program (4 chambers) -3000 chokeberry

0.7.2014/20/8

10.7.2014 / 3752

sector on Montenegro theritory, as well as clinies in private sector. Beside its pharmacies FARMONT directly or indirectly suplies all pharmacies in private TR-JUL-2014

PD:TT

111

tenders, from medicines to consumable medical supplies and equipment In audition to private sector FARMONT has big part in supplying state-health through

phurmaceutical assistants, IT experts and logistic assistants. people of different profiles: workers. Team that Farmont possess is a group of responsible, educated and professional FARMON'I has all services: financial, comercial and delivery service, pharmacists, doctors, economists, biologists, correspondents, brita employs 35

companies, among whom: region and world, in form of legal distributor and exclusive representative of several major Farmout established cooperation and made partnership with many successful companies from

Medicines:

- Abbut USA
- Baster VQ A North Vienna
- Judian Galenski luboratorij-Rijeka, Canatia
- 1138A Switzerland

Medical devices:

- Becton Dickinson
- Boston Scientific
- Elitech
- Schiller
- Tosuma Slovenia.....

FARMONT business profile, among other, is:

- Since its beginning (2001.) FARMONT records, every year, positive results.
- around 15% that in world economy crisis year 2009, increase in turnover and other indicators of business was around 25%, and in last 2010., 2011, and 2012, Increase in turnover was Company has constant turnover increase in average 10 to 15% yearly, with the fact
- FARMONT's bank account since its beginning has never been blocked
- FARMONT credit history is flawless classification A ...
- quality control ... planmacists and a technologist with finished specialized studies FARMONT has its own highly educated staff - wife, son, daughter, and nephow are Industrial chemistry,

PRODUCTION OF MEDICINES AND MARKET

forms and strenght). in every state is of strategic importance, company FARMONT within its plans has production program included five (5) group of medicines and forty names (40) (different Considering that Montenegro as state do not have wide palette production of drugs, which

- Analgesics and antipyreties, (I name)
- Anti inflammatory and anti rheamatic (3 names)
- Medicines for acidity disorder, treatment of peptic ulcer and gastro exophageal reflux
- Medicines that act on cardiovascular system (22 names)
- duti infective medicines for systematic use (8 names)

production in the world is going, particularly in Europe. medicinal herbs is getting more and more important direction in which pharmacentical manufacturing of medicinal and aromatic plants, as production of drugs based on It is significant to emphasize the possibility of technological link of this production with 0.7.2014/20/0

with planned production, be the only manufacturer in Montenegro with a wide range of gastroenterology preparation (Flonivin BS), is fully supplied from import so Farmont will, Montenegro market, except for initision solutions, some ophthalmology drops, and one

almost at the same spending level as in public health, with certain deduction for medical medicines in Montenegro. devices, which means that the amount of 50 million cure is real annual consumption of Tender value for supplying public health is 28,000,000,00 €. Commercial sale is

supplying Montenegro health. much greater participation than planned and cost effective 4.5% to realistic 20 domestic market of minimum 20 - 30 % and more, meaning there are significant reserves for obligations. Having in hind that all domicile factories in the region have a share in their consumption in Mantehogre, which will provide PARMONT relaxed returning of its credit Manufacturing cost, planned by the Project, would be 2.250,000 E, meaning 4,5% of yearly

countries in the region. Export is a reality given that Montenegro has a relaxed economic and other relations with

which Montenegro has agreement for customs duties on goods from Montenegro to Russia with only 1% customs - in the name of customs records. It should be emphasized - ability to export to Russia and countries of former SSSR with

connections with that area we estimate as significant and realistic - ability to export to that fact - minimum burden of export, as well as some FARMON'I business

PROCESING GROWING AND REPURCHASE) AND MARKET 013 MEDICINAL HERBS FOREST FRUITS (PLANTATION

cosmeties, chemical industry etc. characteristics, and are intended for human consumption (as food, beverages and various Products, which would be produced with realization of this program, have well-known spices) or as high quality raw materials for food, pharmaceutical and perfume industries.

biologically healthy food or healthy raw materials, which can be certified. In addition, these products are organic production and can be with great success classified in a

collectors and nanufacturers. plantation growing by its own system of production and cooperate relations with potential mountie herbs. Production program is based on the purchase, wild berries, fruits and vegetables, mushrooms, spice herbs, honey and their collection and processing of medicinal and

Medicinal herbs and forest fruits

1 894,50 TONNS		TOTAL	5
7,501	S.I	EXSCIS	=
1 510,001	WERRY FRUITS	BIRK	
	LC1.8	PRODUCTS	1
15,501	Y AND HONEY 15,501	1:ENOTE	T.
	MI DICAL TEAS	MILL	
AND 35,00 t	FILTER	DOMESTIC	7
16,001		SPICES	()
3,001	MUSIIROOMS	SOM	اليا
and a Charles . The first of the first of the contract of the	VEGITABLES	YEGH	
AND 25,00 1	FRUIT	DRIED	-
2,001	ESSENTIAL OILS	ESSE	نعا
1,00,08	FOREST FRUIT AND SEED	1 OKL	N.
	AROMATIC PLANTS	ARON	
200,501	CINAL AND	MIEDICINAL	-
Striol	The state of the s		1
production			
Yolume	it tipe	Product tipe	

- NOV

10 species of forest finits and seeds and 3-4 types of mushrooms. The product range is defined with about 15 species of medicinal and aromatic herbs, around

for these products both on domestic and international markets. Results of previous knowledge and market researches indicate that there is unlimited demand

products are placed on the foreign market (Germany, Austria, Italy, France, Swiss, SAD, former Yugoslavian countries etc.) - Martin Bauer, Josef Weber (Germany), Dr.Schaur (Italy) Having in mind the scope and range of products. We can conclude that, over 90%

3. CAPITAL INVESTMENT

processing of medicinal herbs and wild fruits and modern distributive centre, it is necessary, by higgest standards in this area (GMP, HASAP....) to build a facility of total gross area of 6.945.61 m2. For realization of Pharmaceutical centre FARMONT which includes drug production,

Н Лоот	I floor.	Ciround I
	*	-
	-	_
8	-	-
-		\simeq
*		-
		-
	38	020
100		4.1
	- 40	
0.5	12	100
2		
*		
	5	
-	*	
*	÷	-
2		-
-	3	
5		
		4
	3	:
20	2	
-		:
		33.66
	4.	
-		
2	9	
	*	
1.163.78 m2	1.163.78 m2	4.618.05 m2
		-
-	_	-
Th.	3	-
-	1.	-
الما	-	~
-		-
~	~	-
20	20	S
	=	_
-	-	-
25 3	W	IV
		0.70 500

Total planned EXEMONT investment in the construction of Business . Production center

oan funds	restor participation	stimated value of Investment	C	
8.560.430.00	1.567.710.00	10.128.140.00	mvestment	total amount of 1 Phase
720.000.00	480.000.00	1.200.000.00	(finished)	1 Phase
7.840.430.00	1.067.710.00	8.918.140.00		II Phase

II FINANCIAL PLAN AND PROJECTIONS

a) Sales forecast by products

period and estimations for next period grove from 5-20% each year. Sale will in next period of time, depending on products, based on experience from earlier

the apparent large but unused potentials of Montenegro market. Ve von can see sale forecast is not aggressive, it can be called as "realistic seemario" despite

b) Existing business lines

Projected income is done on following assumptions:

- Company on existing ownership structure, meaning, without entering a strategic Income projection is done under the assumption of further growth and development of
- next five your period. Business plan, hased on which was identified the possible net eash flow, is made for
- years and 3% per year in last two years and planed income growth in next five years on level of 5% per year in first three Projection was made based on financial results of total income in period 2005-2012

18.7.2014 / 2678

10.7.2014 / 3752

4 Business is projected based on assumption of average total income growth. Income growth by individual lines of business would be different.

e) New business lines - production of drugs - ready made drugs

ophthalmology drops, and one gastroenterology preparation (Flonivin BS), is fully supplied from impart Montenegro murket, ខ្លួន we mentioned before, except for infusion solutions, some

Montenegro As stated above amount 0 50 million curo is real annual consumption of drugs

significant economical reserves of the Program. (4.5%) to real 20-30%, as domestic factories in region cover their markets, which indicates return of the loan, it is obvious that there is large reserve from planed - modest placement Given that in Business plan was entered with market coverage of only 4.5%, what allows

capacities, and economical effects would multiply field "Bayer" and "Artesana"- Germany, in which case would be even better utilization of made conversations and announced possibilities for cooperation with major companies in this At this moment it doesn't calculate a sale possibility on foreign markets, based on already

Costs from this production are done based on common "benchmark" standards in this area

Production and sale forecast:

7.7	=	_					7.0
Total sale:	Drug production	Current activity					Ασίνιιγ
5.680.309 5.964.324	2.250.000	3.430.309 3.601.824					lyear
5.964	2.362.500	3,601					H year
324	500	824				-	ar
	5%	%	year	The April	ξū	campared	Wimory &
6.262.541	2,480.625	3.781.916			19		Schowin III year which
	5%	5%	year	previous	10	paritions	W Hidwith
6.450.417	2.555,044	3.895.373					UMBIN JEBA AL
	3%	3%	7007	previous	, a	compared	W Browth
6,643,929	2.631.695	4.012.234					Vyeur
The common of the	3%	*			pravious year	in paredities	16 Browiti

ę Expense forecast

costs of raw materials and costs of sold goods, other expenses and net finance costs Expenses are divided, according to official form of calculation, in five major categories: direct

on their character (fixed or variable with sub-versions) Costs in mentioned years are based on historic data and their growth is determined depending

following assumptions: In that way, cost projection of Company for monitored period was carried out on the

18.7.2014 / 2678

10.7.2014 / 3752

5,785,504	5,642,526	5,566,368	5,438,669	5,313,515	TOTAL COSTS:
8,000	7,000	6,000	5,000	4,000	Bank services
16,000	14,000	12,000	9,000	7,000	Molnienning expenses
20,000	20,000	20,000	20,000	20,000	Write offs of outstanding claims and supplies
1,100	1,000	900	800	600	Coxis for utilities
1,800	1,600	1,400	1,200	1,000	Property taxes and fees for use of construction land
1,200	1,200	1,200	1,200	1,200	Costs for memberships, Chamber of commerce, Employers umon
70,000	7,000	7,000	7,000	7,000	Authors (eo
29,000	27,000	25,000	22,000	20,000	Expenses for representation and business trips
16,000	15,000	14,000	13,000	12,000	Telephone expenses
9,400	3,200	3,000	2,700	2,500	Vehicle registrations and maintenance
8,000	8,000	8,000	8,000	8,000	Expensis for different kind of intellectual services, sentinars, backs
5,252	5,252	5,252	5,252	5,252	Teller costs
10,000	10,000	10,000	10,000	000,01	Insurance
10,000	000,01	10,000	10,000	10,000	Marketing
343,023	102,679	462,335	521,991	581,647	Funding expenses interests
92,700	92,700	92,700	92,700	92,700	Amontoation of other investment costs of the project
381,867	381,867	381,867	381,867	381,867	Amortization of equipment on level of entire project
98,097	98,097	98,097	98,097	98,097	Construction amortization an level of entire project
101,107	99,124	97,181	95,275	92,500	Manpower costs for drug production
202,213	198,248	194,361	190,550	185,000	Manpawer costs for existing business line
163,783	159,013	154,381	149,885	145,519	Casts for auxiliary materials and maintenance for drugs
247,079	239,882	232,896	226,112	215,345	costs for auxiliary materials and maintenance for axisting business line
48,509	47,097	45,725	44,393	43,100	Fuel and energy cost for drug production
13,944	15,538	13,143	12,761	12,153	Fuel and energy cost for existing business line
844,132	819,545	795,675	772,500	750,000	Direct costs for drug production
3,049,298	2,960,484	2,874,256	2,737,387	2,607,035	Direct custs of goods for existing business line
=	11-14-11-11	The control of the second control of the control of			The second secon
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	V		=		

5070 sayılı kanun göreğince güvenli elektronik ımza ile imzal

ımlıştır. ID 813153768201471511657. Bu kod ile http://evrak.lim.org.ti/ adrosinden doğrulsyabilistiniz

10.7.2014 / 3752

Projected balance sheet and eash flow

level of app. 20%). projection (current ratio of net profit and total income in Montenegro, in this industry, on with what is best confirmed pessimistic but because of that even sufer approach in cost "Furniont" expects to conclude first year with not profit in the amount of 333.783 ϵ and fifth year with net profit in amount of 781.167 ϵ , which is 11.76 % compared to volume of sale;

This growth is a result of increase in total income and reduced costs ("intern economy")

On next page is given table of projected balance sheet

	ANCE SHEET WITH PROJECT			Ī								
No	POSITION / Year	0	1	2	, 3	4	5	6	7	8	9	10
1	Income	D	5.680.309	5.964.324	6.262 541	6.450.417	6.643.929	6.643.929	6.643.929	6.643.929	6.643.929	6.643.929
2	Other business gains	D	; C	0	0	0	0	0	0	0	0	D
3	Executed, capitalized labor for own purposes	0	D	S	0	0	0	0	0	0	O.	0
1	Changes in inventories (finished goods and unfinished	0										
5	production) Consumed materials	0	0	0	0	0	C	0	Û	0	0	0
5	Costs for employees	0		3,943,037	4,116,076		4,366,745		4,366,745	4,366,745	4,366,745	4,366,745
		0	277,500	285,825	291,542	297,372	303,320	303,320	303,320	303,320	303,320	303,320
· ·	Amortization	0	572,664	572,664	572,664	572,664	572,664	572,664	572,664	572,664	572,664	572,664
8	Other business outgoings	0	108,552	115,152	123,752	130,252	199,752	199,752	199,752	199,752	199,752	199,752
	Profit from business activities	0	948.441	1.047.646	1.158.507	1.210.571	1.201.448	1.201.448	1 201 448	1.201.448	1.201.448	1.201.448
9	Net financial costs	0	581,647	521,991	462,335	402,679	343,023	283,367	223,710	164,054	104,398	44,742
10	Income from associated companies	0	0	0	0	0	0	0	0	0	0	0
11	Income tax	0	33.011	47.309	62.655	72.710	77.258	82.627	87.996	93.365	98.734	104.104
	Profit after taxation	0	333.783	478.345	633.517	735.182	781.167	835.454	889.742	944.029	998.316	1.052.602
12	Minority Interests	0	10	0	0	0	0	0	0	0	0	0
	Net profit from business activities	0	333.783	478.346	633.517	735.182	781.167	835.454	889.742	944.029	998316	1.052.602
13	Unexpected items	0	0	0	0	0	0	0	0	0	0	0
	Net profit / loss for the accounting period	0	333.783	478.346	633.517	735.182	781.167	835.454	889.742	944.029	998316	1.052.602

5070 sayılı kanun gereğince gür

venli elektronik imza ile imzalemnistir. ID:81315376620147161657. Bu kod ile http://evrak.tim.org.tr/ adresinden doğrulayabilirsinis

10	7.201	4 4 1	275	٦.
163	6 /11	14 /	5/7	Į

IANGAL PROJECTIONS WITH PROJECT ICAS	H FLOW)										
ELEMENT / YEAR	0	1	2	3	4	5	6	7	8	9	10
START CASH	0	0	11.340	144.563	432.957	826.016	1.262.060	1.752.391	2.297.010	2.895.916	3.549.109
CASH FROM BUSINESS ACTIVITIES	0	906.447	1.051.010	1.206.181	1.310.846	1.353.831	1.408 118	1.462.406	1.516.693	1.570.980	1.625.265
Net profit	D	333.783	478.346	633.517	735.182	781.167	835.454	889.742	944.029	998.315	1.052.602
Amortization	ð	572,664	572,664	572,664	572,664	572,664	572,564	572,664	572 664		572,664
Decrease (+) / Increase (-) receivables	0	0	J.	0	0	e	0	0	0		0
Decrease (+) / Increase (-) supplier obligations	0	0	0	0	0	0	0	0	0	C	0
Other	0	0	0	0	0	0	- 0	0	0	0	0
INVESTMENT ACTIVITY	0	0	C	0	D	0	0	0	<u>d</u> ———	0	0
Investments (-)/ disinvestments											
(+) in supplies	0	0	0	0	0	0	0	0	0	0	0
Construction	: 0	0	0	0	0	0	0	0	0	0	D
Renovation	0	0	O	0	0	0	O	0	0	0	0
Machines and equipment (replacement)	0	0	0	D	0	0	0	0	0	0	0
FINANCING	7,597,880	917,787	917,787	917,787	917,787	917,787	917,787	917,787	9:7.787	917.787	917,787
Increase in debt / loan	7,597,880	0	0	0	0	0		0	0	0	D
Repayment of main part/principal	0	917,787	917,787	917,787	917,787	917,787	917,787	917,787	9: 7,787	917,787	917,787
Own investments	0	. 0	D	C	0	0	0	0	0	0	0
CASH AT THE END OF PERIOD	. 0	11.340	144.563	432.957	826.016	1.262.060	1.752.391	2.297.010	2.895.916	3.549.109	4.256.588
NET FLOW (GROWT) OF CASH	0	11.340	133.223	299.734	393.059	436.044	490.331	544.619	558.906	653.193	707.479
	ELEMENT / YEAR START CASH CASH FROM BUSINESS ACTIVITIES Net profit Amortization Decrease (+) / Increase (-) receivables Decrease (+) / Increase (-) supplier obligations Other INVESTMENT ACTIVITY Investments (-) / disinvestments (+) in supplies Construction Renovation Machines and equipment (replacement) FINANCING Increase in debt / loan Repayment of main part/principal Own investments	START CASH CASH FROM BUSINESS ACTIVITIES Net profit Amortization Decrease (+) / Increase (-) receivables Decrease (+) / Increase (-) supplier obligations Other INVESTMENT ACTIVITY Investments (-) / disinvestments (+) in supplies Construction Renovation Machines and equipment (replacement) FINANCING Increase in debt / loan Repayment of main part/principal Own investments O CASH AT THE END OF PERIOD O	START CASH	ELEMENT / YEAR	ELEMENT / YEAR	ELEMENT YEAR 0					

10.7.2014 / 3752

IM

Resume

This excerpt from the Business Plan is intended to interest business partners to finance or co-finance of II Phase of the project - PRODUCTION OF DRUGS AND PROCESSING OF MEDICINAL HERBS AND FOREST FRUITS, as well as those business partners which would through collaboration with FARMONT get a FARMONT, or through other forms of cooperation with it. possibility for significant share of the Montenegro health market through - deliveries in IN BULK forms to

distribution activities, FARMONT has linished Phase I, which created conditions for Contemporary Secondary packaging and modern

Therefore we believe that at this point following should be considered:

- Through strategic partnerships with deliveries to FARMONT, IN BULK products in blisters supplier gets the treatment of domicile manufacturer on Montenegro market (50 mil Eur).
- emphasized ability to export to Russia and countries of former SSSR with which Montenegro has name of customs records. agreement for customs duties on goods from Montenegro to Russin with only 1% Possibility for export is evident in countries of the region and wider, but it should be specially customs - in the
- favorable conditions for this type of investment. Possibility of financing II Phase of Investment Project in the amount of 7.840.430.00 €, under

For any other information, please, do not besitate to contact me any time

BR,

Skype: mladen.vukovie99 Tel: +382 69 670497 Dr. M. Vukovic, D.M.D. +381 63 8921300